Adaptive Biotechnologies Corp vs iShares Bitcoin Trust — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while iShares Bitcoin Trust trades at $36.03. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| ADPT | IBIT | |
|---|---|---|
Market Cap | $4.05B | — |
Sector | Health | Crypto-linked |
52-Week High | $25.45 | $71.29 |
52-Week Low | $12.30 | $33.29 |
Enterprise Value | $4.12B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
IBIT trades at $36.80, up 0.85% today, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $36 and resistance at $37. Recent news highlights strong institutional interest, with BlackRock's head of digital assets noting 'overwhelming demand' for crypto ETFs (Bloomberg, 2026-08-10).
The outlook is cautiously optimistic given technical strength and institutional inflows, but risks include Bitcoin price volatility and regulatory uncertainty. Analyst sentiment is mixed, with some recommending long-term buys amid crypto market downturns.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →